Quantifies brain function
down to the voxel level

CereMetrix Silver neuroimaging analytics platform scores FDA approval

March 20, 2018
by Lauren Dubinsky, Senior Reporter
CereMetrix announced on Tuesday that its CereMetrix Silver neuroimaging analytics and quantification platform received FDA approval.

Shane Quint, CTO of CereMetrix, told HCB News that this platform is ideal for any providers who treat patients with mental/brain health issues including independent diagnostic facilities, radiologists, neurologists, etc.

The platform is designed to evaluate brain PET, SPECT, MR and CT scans. It performs what’s called cluster analysis, which involves the quantitative and statistical analysis of SPECT brain scans by comparing them to other registered SPECT brain scans.

It also enables the reading physician to localize and define brain function and differentiate between hyper and hypo function in the brain. With viewports, they can process and display the image data in 2-D formats while simultaneously displaying pseudo 3-D renderings.

The platform can also aid in the assessment of quantitative SPECT (qSPECT) brain scans. Once the brain imaging data is reconstructed, the platform maps it to a common brain template and anatomical map before applying a clustering algorithm.

“Using other software products on the market today, the physician is required to subjectively identify areas of hypo/hyper function by their experience in knowing what perfusion should look like in a specific region of the brain,” said Quint.

He added that CereMetrix Silver compares patients' brain blood flow to an average voxel-level blood flow calculated using, currently, 1,000 patient images. And that number is growing with every patient scanned.